AcelRx Pharmaceuticals (ACRX) Stock Price
AcelRx Pharmaceuticals Price
Revenue at AcelRx Pharmaceuticals has contracted by 4.1% per year over the past 12 years to 651,000.00 USD. AcelRx Pharmaceuticals's net margin stands at -1,580.2%, up from -2,325.9% several years earlier. Of 8 analysts, 7 rate the stock a buy — an overall Buy consensus.
AcelRx Pharmaceuticals stock price
AcelRx Pharmaceuticals business model & stock analysis
Frequently asked questions about AcelRx Pharmaceuticals
The business model of AcelRx Pharmaceuticals Inc. revolves around the development and commercialization of innovative therapies for acute pain management. As a specialty pharmaceutical company, AcelRx focuses on designing and delivering precise, non-invasive treatment options to improve patient outcomes. With a particular emphasis on the hospital setting, AcelRx aims to address the unmet needs of healthcare professionals and patients by providing advanced, user-friendly medication delivery systems. By leveraging its proprietary platform technology, AcelRx develops and markets novel products that enhance pain management and sedation practices, ultimately enhancing patient care and discomfort alleviation.
AcelRx Pharmaceuticals Inc is primarily active in the pharmaceutical industry.
The main competitors of AcelRx Pharmaceuticals Inc in the market are companies such as Pfizer Inc., Johnson & Johnson, and Teva Pharmaceutical Industries Ltd. These companies compete with AcelRx Pharmaceuticals Inc in the field of innovative pharmaceutical products and solutions. While AcelRx Pharmaceuticals Inc is known for its specialized focus on developing and commercializing therapies for acute pain management, these competitors have a broad portfolio of pharmaceutical offerings in various therapeutic areas. As the market continues to evolve, AcelRx Pharmaceuticals Inc faces competition from these established players, stimulating innovation and driving advancements in the pharmaceutical industry.
AcelRx Pharmaceuticals Inc is a biopharmaceutical company based in Redwood City, California. Founded in 2005, AcelRx is focused on the development and commercialization of innovative therapies for the treatment of acute pain. The company specializes in developing solutions that enhance the safety, efficacy, and convenience of acute pain management. AcelRx has an extensive portfolio of products, including its flagship product, DSUVIA® (sufentanil sublingual tablet), which was approved by the U.S. FDA in 2018 for the management of acute pain in a medically supervised setting. With a commitment to advancing pain management options, AcelRx Pharmaceuticals Inc is dedicated to improving the lives of patients worldwide.
AcelRx Pharmaceuticals Inc has achieved significant milestones in its development. The company successfully gained FDA approval for their innovative drug Dsuvia, which offers a non-invasive pain relief method for patients. Additionally, AcelRx Pharmaceuticals Inc has expanded its market presence by partnering with major healthcare organizations, enabling wider distribution of their products. The company has also shown progress in clinical trials, consistently meeting important endpoints and showcasing the effectiveness of their therapeutics. AcelRx Pharmaceuticals Inc's commitment to innovation and their track record of achievements have positioned them as a leader in the pharmaceutical industry.
AcelRx Pharmaceuticals Inc is primarily present in the United States.
AcelRx Pharmaceuticals Inc represents a strong commitment to excellence, innovation, and patient care. With a focus on developing and delivering advanced therapies, AcelRx Pharmaceuticals Inc strives to improve the lives of patients suffering from acute pain. The company's corporate philosophy is guided by a dedication to ethics, integrity, and continuous improvement. By leveraging cutting-edge technologies and scientific expertise, AcelRx Pharmaceuticals Inc aims to provide safe and effective treatment options. As leaders in the pharmaceutical industry, their patient-centric approach and dedication to research and development make them a trusted choice for healthcare professionals and patients alike.
8 analysts currently rate the AcelRx Pharmaceuticals stock: 7 recommend buying, 1 holding and 0 selling. For 2026, analysts expect AcelRx Pharmaceuticals to generate revenue of 12.58 M USD and earnings per share of -0.58 USD.
The AcelRx Pharmaceuticals share (ACRX) is listed on 3 stock exchanges, including: NASDAQ (ACRX), Frankfurt (R5X.F), München (R5X.MU).
AcelRx Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative pain treatment solutions. The company is headquartered in California, USA and was founded in 2005.
The expected revenue of AcelRx Pharmaceuticals is 12.58 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of AcelRx Pharmaceuticals is -9.77 M USD. The net profit reflects the company's profitability after deducting all expenses.
The P/E ratio cannot be calculated for AcelRx Pharmaceuticals at the moment.
The P/S cannot be calculated for AcelRx Pharmaceuticals currently.
The Eulerpool Quality Score for AcelRx Pharmaceuticals is 2/10.
The ISIN of AcelRx Pharmaceuticals is US00444T1007. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of AcelRx Pharmaceuticals is A1H64B. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of AcelRx Pharmaceuticals is ACRX. The ticker symbol is used to trade AcelRx Pharmaceuticals shares on the stock exchange.
AcelRx Pharmaceuticals stock
AcelRx Pharmaceuticals Peer Group
AcelRx Pharmaceuticals Ticker
AcelRx Pharmaceuticals FIGI
All fundamentals and in-depth analysis of AcelRx Pharmaceuticals
Our stock analysis for AcelRx Pharmaceuticals stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of AcelRx Pharmaceuticals. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.